ALBRIOZA(AMX0035) Approved as a Treatment for ALS in Canada with Conditions
June 15, 2022
Amylyx Pharmaceuticals, Inc announced that Health Canada has approved ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c). This decision came after a nearly 300-day review of the drug’s safety, efficacy…
Read More >>